AZD1152 in Patients With Advanced Solid Malignancies

Completed · Phase 1

Conditions studied: Tumors

In brief

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Key facts

Study ID

NCT00338182

Run by

AstraZeneca

People needed

43

Starts

2006-05-23

Expected to finish

2017-03-01

Last updated by the study team

2017-04-24

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological or cytological confirmation of a solid, malignant tumour
• At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

You may not qualify if…

• Participation in an investigational drug study within the 21 days prior to therapy or those who have not recovered from the effects of an investigational study drug
• Recent major surgery within 4 weeks prior to entry into the study

Where it is running

• Research Site — Boston, Massachusetts, United States
• Research Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.